Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m (→Gastric cancer) |
m (→Also known as) |
||
(17 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | ||
− | = | + | ==Diseases for which it is established ''(work in progress)''== |
+ | *[[Hepatocellular carcinoma]] | ||
− | ==[[Gastric cancer]] | + | ==Diseases for which it is used== |
− | + | *[[Esophageal cancer]] | |
+ | **[[Esophageal adenocarcinoma]] | ||
+ | *[[Gastric cancer]] | ||
+ | *[[Non-small cell lung cancer, EGFR-mutated]] | ||
+ | *[[Thyroid cancer, differentiated]] | ||
− | + | ==Also known as== | |
− | + | *'''Code name:''' YN-968D1 | |
− | + | *'''Generic name:''' rivoceranib | |
+ | *'''Brand name:''' Aitan | ||
− | [[Category: | + | [[Category:Drugs]] |
− | [[Category: | + | |
+ | [[Category:Oral medications]] | ||
+ | |||
+ | [[Category:VEGFR inhibitors]] | ||
[[Category:KIT inhibitors]] | [[Category:KIT inhibitors]] | ||
[[Category:SRC inhibitors]] | [[Category:SRC inhibitors]] | ||
+ | [[Category:Esophageal cancer medications]] | ||
+ | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
+ | [[Category:Hepatocellular carcinoma medications]] | ||
+ | [[Category:Non-small cell lung cancer medications]] | ||
+ | [[Category:Thyroid cancer, differentiated medications]] | ||
− | [[Category: | + | [[Category:NMPA approved drugs]] |
Latest revision as of 02:08, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is established (work in progress)
Diseases for which it is used
- Esophageal cancer
- Gastric cancer
- Non-small cell lung cancer, EGFR-mutated
- Thyroid cancer, differentiated
Also known as
- Code name: YN-968D1
- Generic name: rivoceranib
- Brand name: Aitan